sample of publications

• articles 

  • Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study.  EXPERIMENTAL DERMATOLOGY.  33:1-13. 2024
  • Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa.  BRITISH JOURNAL OF DERMATOLOGY.  189:774-776. 2023
  • FPR2 DNA Aptamers for Targeted Therapy of Wound Repair.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  142:2238-2248. 2022
  • CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative.  CLINICAL GENETICS.  101:481-493. 2022
  • Evaluation of systemic gentamicin as translational readthrough therapy for a patient with epidermolysis bullosa simplex with muscular dystrophy owing to PLEC1 pathogenic nonsense variants.  JAMA Dermatology.  158:439-443. 2022
  • Hallmarks of the human intestinal microbiome on liver maturation and function.  JOURNAL OF HEPATOLOGY.  76:694-725. 2022
  • Molecular characterization of the response to haploidentical mesenchymal stem cells treatment in recessive dystrophic epidermolysis bullosa patients.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  141:S176-S176. 2021
  • Transcriptomic Analysis of a Diabetic Skin-Humanized Mouse Model Dissects Molecular Pathways Underlying the Delayed Wound Healing Response.  Genes.  12 (1):1-13. 2020
  • Combined adipose mesenchymal stromal cell advanced therapy resolved a recalcitrant leg ulcer in an 85-year-old patient.  Regenerative Medicine.  15:2053-2065. 2020
  • Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: A case report.  Frontiers in Medicine.  7:1-12. 2020
  • Raloxifene and n-Acetylcysteine ameliorate TGF-signalling in fibroblasts from patients with recessive dominant epidermolysis bullosa.  Cells.  9:1-18. 2020
  • Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain.  Clinical & Translational Oncology.  21:1573-1577. 2019
  • Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.  BRITISH JOURNAL OF DERMATOLOGY.  181:512-522. 2019
  • Phase I/II efficacy and safety study of mesenchymal stromal cells in recessive dystrophic epidermolysis bullosa.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  139:S236-S236. 2019
  • Amperometric determination of endoglin in human serum using disposable immunosensors constructed with poly(pyrrolepropionic) acid-modified electrodes.  ELECTROCHIMICA ACTA.  292:887-894. 2018
  • Terapias avanzadas en enfermedades raras = Advanced therapies for rare diseases.  Arbor.  194:1-15. 2018
  • Long-term skin regeneration in xenografts from iPSC teratoma-derived human keratinocytes.  EXPERIMENTAL DERMATOLOGY.  25:736-738. 2016
  • Increased Susceptibility to Skin Carcinogenesis Associated with a Spontaneous Mouse Mutation in the Palmitoyl Transferase Zdhhc13 Gene.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  135:3133-3143. 2015
  • Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.  Oncotarget.  5:1439-1451. 2014
  • Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  134:571-574. 2014
  • The regenerative potential of fibroblasts in a new diabetes-induced delayed humanised wound healing model.  EXPERIMENTAL DERMATOLOGY.  22:195-201. 2013
  • Bioingeniería cutánea: aplicaciones preclínicas y clínicas = Skin bioengineering: preclinical and clinical applications.  Actas Dermo-Sifiliograficas.  103:5-11. 2012
  • Skin bioengineering: preclinical and clinical application = Bioingeniería cutánea: aplicaciones preclínicas y clínicas.  Actas Dermo-Sifiliograficas.  103:5-11. 2012
  • Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis bullosa simplex.  BRITISH JOURNAL OF DERMATOLOGY.  165:683-692. 2011
  • Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement.  JOURNAL OF INVESTIGATIVE DERMATOLOGY.  128:1565-1575. 2008

• book chapters 

  • Organotypic and humanized animal models of genodermatoses. In: Skin tissue models.  Academic Press. 77-102. 2018
  • Bioengineered Skin. In: Skin Biopsy: Perspectives.  INTECH. 261-296. 2011

• conference contributions 

  • Systemic metabolomics in recessive dystrophic epidermolysis bullosa paediatric patients to determine therapeutic mechanisms of mesenchymal stem cells.  13-13. 2021
  • Preliminary safety and efficacy outcomes of a phase I trial of systemic mesenchymal stromal cells for recessive dystrophic epidermolysis bullosa.  57-57. 2020
  • 319 First-in-human treatment of recessive dystrophic epidermolysis bullosa with adipose derived mesenchymal stromal cells. A case report.  S269-S269. 2019
  • Safety criteria and patient selection in a cell-based clinical trial for the systemic treatment of recessive dystrophic epidermolysis bullosa: MesenSistem-EB 2019
  • Assessment of the performance and fate of adipose-derived mesenchymal stem cells forming part of bioengineered skin equivalents in vitro and in vivo.  99. 2014
  • Cell-based therapy for diabetic wounds: from the bench to the patient 2013
  • Capturing the biological impact of the status of CDKN2A and MC1R genes in cocultures human keratinocytes and melanocytes: identification of deregulated pathways 2012
  • In-silico protein-protein interaction networks in cocultures melanocytes and keratinocytes evidences of autophagy genes invoved in melanogenesis 2012
  • Protein-protein interaction networks in cocultured melanocytes and keratinocytes regarding the genomic status of CDKN2A and MC1R genes.  130-130. 2012
  • The presence of red hair MC1R variants enhance melanoma sun-induced susceptibility in a CDKN2A skin-humanized mice model of cutaneous familiar melanoma.  130-130. 2012
  • Transcriptome profiling in a delayed wound healing skin-humnized mouse model revealed genes implicated in extracellular matrix remodeling and collagen deposition.  11-11. 2012
  • Human fibroblasts in skin regeneration: A preclinical study in diabetic wound healing.  2-2. 2011
  • In vitro disadvantage of type XVII collagen revertant keratinocytes when cultured for revertant cell therapy.  69-69. 2011
  • Transcriptome variation in human keratinocytes and melanocytes regarding the genomic status of CDKN2A and MC1R genes.  113-113. 2011